CASR
entrez
846
canonical
uniprot
P41180
canonical
ensembl
ENSG00000036828
resolver
ensp
ENSP00000420194
resolver
ensp
ENSP00000491584
resolver
ensp
ENSP00000492190
resolver
ensp
ENSP00000521158
resolver
genesymbol
CASR
resolver
genesymbol_syn
GPRC2A
resolver
genesymbol_syn
PCAR1
resolver
hgnc
HGNC:1514
resolver
uniprot
Q13912
resolver
uniprot
Q16108
resolver
uniprot
Q16109
resolver
uniprot
Q16110
resolver
uniprot
Q16379
resolver
uniprot
Q2M1T0
resolver
uniprot
Q4PJ19
resolver
uniprot_entry
CASR_HUMAN
resolver
uniprot_sec
Q13912
resolver
uniprot_sec
Q16108
resolver
uniprot_sec
Q16109
resolver
uniprot_sec
Q16110
resolver
uniprot_sec
Q16379
resolver
uniprot_sec
Q2M1T0
resolver
uniprot_sec
Q4PJ19
resolver
activity_regulation
ACTIVITY REGULATION: In resting state, adopts an open conformation, anion-binding promoting the inactive configuration (PubMed:27434672). Upon aromatic amino acid-binding, the groove in the extracellular venus flytrap module is closed, thereby inducing the formation of a novel homodimer interface between subunits (PubMed:27386547, PubMed:27434672). Calcium ions stabilize the active state by enhancing homodimer interactions between membrane-proximal domains to fully activate the receptor (PubMed:27386547, PubMed:27434672). Upon activation, the homodimer adopts an asymmetric configuration of the 7-transmembrane region that primes one protomer for G protein coupling (PubMed:34194040, PubMed:37919470). G protein binding expands the transmembrane dimer interface; the restriction imposed by the receptor dimer, in combination with intracellular loop 2 (ICL2), enables G protein activation by facilitating conformational transition of G protein alpha (PubMed:38326620, PubMed:38632411). Coupling to different classes of G proteins results in distinct CASR-G protein interfaces (PubMed:38326620). Activated by glucose, which acts as a positive allosteric modulator (PubMed:27613866). Activated by positive allosteric modulator drugs cinacalcet, evocalcet and etelcalcetide, which are clinically used for the treatment of hyperparathyroidism and familial hypocalciuric hypercalcemia (PubMed:34194040). Inhibited by NPS-2143, a negative allosteric modulator tested for the treatment of hypocalcemia (PubMed:34194040). Activated by velcalcetide (AMG 416), a D-amino acid-containing peptide agonist that is being evaluated for the treatment of secondary hyperparathyroidism in chronic kidney disease patients receiving hemodialysis (PubMed:26290606). Velcalcetide agonist acts by forming a disulfide bond with Cys-482 (PubMed:26290606). {ECO:0000269|PubMed:26290606, ECO:0000269|PubMed:27386547, ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:27613866, ECO:0000269|PubMed:34194040, ECO:0000269|PubMed:37919470, ECO:0000269|PubMed:38326620, ECO:0000269|PubMed:38632411}.
uniprot
proteins
amino_acid_sequence
MAFYSCCWVLLALTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREVPFSNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACNKCPDDFWSNENHTSCIAKEIEFLSWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLLCCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWWGLNLQFLLVFLCTFMQIVICVIWLYTAPPSSYRNQELEDEIIFITCHEGSLMALGFLIGYTCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVIAILAASFGLLACIFFNKIYIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRSNVSRKRSSSLGGSTGSTPSSSISSKSNSEDPFPQPERQKQQQPLALTQQEQQQQPLTLPQQQRSQQQPRCKQKVIFGSGTVTFSLSFDEPQKNAMAHRNSTHQNSLEAQKSSDTLTRHEPLLPLQCGETDLDLTVQETGLQGPVGGDQRPEVEDPEELSPALVVSSSQSFVISGGGSTVTENVVNS
uniprot
proteins
disease_involvement
DISEASE: Hypocalciuric hypercalcemia, familial 1 (HHC1) [MIM:145980]: A form of hypocalciuric hypercalcemia, a disorder of mineral homeostasis that is transmitted as an autosomal dominant trait with a high degree of penetrance. It is characterized biochemically by lifelong elevation of serum calcium concentrations and is associated with inappropriately low urinary calcium excretion and a normal or mildly elevated circulating parathyroid hormone level. Hypermagnesemia is typically present. Affected individuals are usually asymptomatic and the disorder is considered benign. However, chondrocalcinosis and pancreatitis occur in some adults. {ECO:0000269|PubMed:10077597, ECO:0000269|PubMed:11762699, ECO:0000269|PubMed:11807402, ECO:0000269|PubMed:15572418, ECO:0000269|PubMed:15579740, ECO:0000269|PubMed:15879434, ECO:0000269|PubMed:16598859, ECO:0000269|PubMed:16740594, ECO:0000269|PubMed:17473068, ECO:0000269|PubMed:17698911, ECO:0000269|PubMed:19179454, ECO:0000269|PubMed:19789209, ECO:0000269|PubMed:20798521, ECO:0000269|PubMed:21566075, ECO:0000269|PubMed:21643651, ECO:0000269|PubMed:22114145, ECO:0000269|PubMed:23169696, ECO:0000269|PubMed:23966241, ECO:0000269|PubMed:25104082, ECO:0000269|PubMed:25292184, ECO:0000269|PubMed:26386835, ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:33603117, ECO:0000269|PubMed:34467854, ECO:0000269|PubMed:7673400, ECO:0000269|PubMed:7726161, ECO:0000269|PubMed:7916660, ECO:0000269|PubMed:8636323, ECO:0000269|PubMed:8702647, ECO:0000269|PubMed:8878438, ECO:0000269|PubMed:9298824}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Hyperparathyroidism, neonatal severe (NSHPT) [MIM:239200]: A disorder characterized by severe hypercalcemia, bone demineralization, and failure to thrive usually manifesting in the first 6 months of life. If untreated, NSHPT can be a devastating neurodevelopmental disorder, which in some cases is lethal without parathyroidectomy. {ECO:0000269|PubMed:14985373, ECO:0000269|PubMed:15572418, ECO:0000269|PubMed:17555508, ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:8675635, ECO:0000269|PubMed:8878438, ECO:0000269|PubMed:9253359}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Hypocalcemia, autosomal dominant 1 (HYPOC1) [MIM:601198]: A disorder of mineral homeostasis characterized by blood calcium levels below normal, and low or normal serum parathyroid hormone concentrations. Disease manifestations include mild or asymptomatic hypocalcemia, paresthesias, carpopedal spasm, seizures, hypercalciuria with nephrocalcinosis or kidney stones, and ectopic and basal ganglia calcifications. Few patients manifest hypocalcemia and features of Bartter syndrome, including hypomagnesemia, hypokalemia, metabolic alkalosis, hyperreninemia, and hyperaldosteronemia. {ECO:0000269|PubMed:10487661, ECO:0000269|PubMed:12050233, ECO:0000269|PubMed:12107202, ECO:0000269|PubMed:12241879, ECO:0000269|PubMed:12574188, ECO:0000269|PubMed:12915654, ECO:0000269|PubMed:15005845, ECO:0000269|PubMed:15551332, ECO:0000269|PubMed:16608894, ECO:0000269|PubMed:17048213, ECO:0000269|PubMed:19179454, ECO:0000269|PubMed:22789683, ECO:0000269|PubMed:23169696, ECO:0000269|PubMed:23966241, ECO:0000269|PubMed:25766501, ECO:0000269|PubMed:39658204, ECO:0000269|PubMed:7874174, ECO:0000269|PubMed:8702647, ECO:0000269|PubMed:8733126, ECO:0000269|PubMed:8813042, ECO:0000269|PubMed:8878438, ECO:0000269|PubMed:9253358, ECO:0000269|PubMed:9661634, ECO:0000269|PubMed:9920108}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Epilepsy, idiopathic generalized 8 (EIG8) [MIM:612899]: A disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Seizure types are variable, but include myoclonic seizures, absence seizures, febrile seizures, complex partial seizures, and generalized tonic-clonic seizures. {ECO:0000269|PubMed:18756473, ECO:0000269|PubMed:20798521}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.
uniprot
proteins
function
FUNCTION: G protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis (PubMed:17555508, PubMed:19789209, PubMed:21566075, PubMed:22114145, PubMed:22789683, PubMed:23966241, PubMed:25104082, PubMed:25292184, PubMed:25766501, PubMed:26386835, PubMed:32817431, PubMed:33603117, PubMed:34194040, PubMed:34467854, PubMed:7759551, PubMed:8636323, PubMed:8702647, PubMed:8878438). Senses fluctuations in the circulating calcium concentration: activated by elevated circulating calcium, leading to decreased parathyroid hormone (PTH) secretion in parathyroid glands (By similarity). In kidneys, acts as a key regulator of renal tubular calcium resorption (By similarity). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors (PubMed:38632411). CASR is coupled with different G(q)/G(11), G(i)/G(o)- or G(s)-classes of G proteins depending on the context (PubMed:38632411). In the parathyroid and kidney, CASR signals through G(q)/G(11) and G(i)/G(o) G proteins: G(q)/G(11) coupling activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers, while G(i)/G(o) coupling mediates inhibition of adenylate cyclase activity (PubMed:38632411, PubMed:7759551). The G protein-coupled receptor activity is activated by a co-agonist mechanism: aromatic amino acids, such as Trp or Phe, act concertedly with divalent cations, such as calcium or magnesium, to achieve full receptor activation (PubMed:27386547, PubMed:27434672, PubMed:32817431, PubMed:33603117, PubMed:34194040). Acts as an activator of the NLRP3 inflammasome via G(i)/G(o)-mediated signaling: down-regulation of cyclic AMP (cAMP) relieving NLRP3 inhibition by cAMP (PubMed:32843625). Acts as a regulator of proton-sensing receptor GPR68 in a seesaw manner: CASR-mediated signaling inhibits GPR68 signaling in response to extracellular calcium, while GPR68 inhibits CASR in presence of extracellular protons (By similarity). {ECO:0000250|UniProtKB:P48442, ECO:0000250|UniProtKB:Q9QY96, ECO:0000269|PubMed:17555508, ECO:0000269|PubMed:19789209, ECO:0000269|PubMed:21566075, ECO:0000269|PubMed:22114145, ECO:0000269|PubMed:22789683, ECO:0000269|PubMed:23966241, ECO:0000269|PubMed:25104082, ECO:0000269|PubMed:25292184, ECO:0000269|PubMed:25766501, ECO:0000269|PubMed:26386835, ECO:0000269|PubMed:27386547, ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:32817431, ECO:0000269|PubMed:32843625, ECO:0000269|PubMed:33603117, ECO:0000269|PubMed:34194040, ECO:0000269|PubMed:34467854, ECO:0000269|PubMed:38632411, ECO:0000269|PubMed:7759551, ECO:0000269|PubMed:8636323, ECO:0000269|PubMed:8702647, ECO:0000269|PubMed:8878438}.
uniprot
proteins
mass_dalton
120675
uniprot
proteins
mutagenesis
MUTAGEN 27; /note="Q->E: Increased G protein-coupled receptor signaling."; /evidence="ECO:0000269|PubMed:39658204"; MUTAGEN 29; /note="K->A,N,E,D: Increased calcium sensitivity."; /evidence="ECO:0000269|PubMed:15005845"; MUTAGEN 29; /note="K->R: Does not affect calcium sensitivity."; /evidence="ECO:0000269|PubMed:15005845"; MUTAGEN 51; /note="L->A: Decreased calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:33603117"; MUTAGEN 69; /note="R->E: Abolishes G protein-coupled receptor signaling pathway."; /evidence="ECO:0000269|PubMed:27434672"; MUTAGEN 70; /note="W->A: Abolished calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:33603117"; MUTAGEN 102; /note="N->I: Abolishes G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:27434672"; MUTAGEN 145; /note="T->A: Abolished calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:33603117"; MUTAGEN 145; /note="T->I: Reduced calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:34467854"; MUTAGEN 147; /note="S->A: Abolished calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:33603117, ECO:0000269|PubMed:34467854"; MUTAGEN 170; /note="S->A: Abolished calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:32817431, ECO:0000269|PubMed:33603117, ECO:0000269|PubMed:34467854"; MUTAGEN 170; /note="S->K: Reduced calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:34467854"; MUTAGEN 190; /note="D->A: Reduced calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:32817431"; MUTAGEN 190; /note="D->K: Reduced calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:34467854"; MUTAGEN 193; /note="Q->A: Reduced calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:32817431"; MUTAGEN 216; /note="D->A: Strongly reduced calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:32817431"; MUTAGEN 218; /note="Y->A: Abolished calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:32817431, ECO:0000269|PubMed:33603117"; MUTAGEN 218; /note="Y->S: Abolished calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:34467854"; MUTAGEN 272; /note="S->A: Does not affect calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:32817431"; MUTAGEN 275; /note="D->A: Does not affect calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:32817431"; MUTAGEN 297; /note="E->A: Abolished calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:32817431, ECO:0000269|PubMed:33603117"; MUTAGEN 297; /note="E->I: Abolishes ability to sense calcium or magnesium levels."; /evidence="ECO:0000269|PubMed:27386547"; MUTAGEN 417; /note="S->L: Abolishes G protein-coupled receptor signaling pathway."; /evidence="ECO:0000269|PubMed:27434672"; MUTAGEN 444; /note="F->A: Decreased calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:33603117"; MUTAGEN 458; /note="W->A: Decreased calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:33603117"; MUTAGEN 482; /note="C->S,Y: Abolishes ability of agonist AMG 416 to activate G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:26290606"; MUTAGEN 489; /note="Y->F: Reduced calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:34467854"; MUTAGEN 603..605; /note="IEF->AEA: Decreased calcium sensitivity."; /evidence="ECO:0000269|PubMed:33603117"; MUTAGEN 706; /note="F->A: Abolished calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38632411"; MUTAGEN 709; /note="K->A: Does not affect G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 710; /note="I->A: Does not affect G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 711; /note="P->A: Does not affect G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 712..714; /note="TSF->ASA: Decreased G(q)-mediated G protein-coupled receptor activity without affecting G(i)-mediated G protein-coupled signaling."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 716..719; /note="RKWW->AKWA: Decreased G(i)-mediated G protein-coupled receptor activity without affecting G(q)-mediated G protein-coupled signaling."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 761..763; /note="IFI->AAA: Decreased calcium sensitivity."; /evidence="ECO:0000269|PubMed:33603117"; MUTAGEN 762; /note="F->A: Decreased calcium sensitivity."; /evidence="ECO:0000269|PubMed:33603117"; MUTAGEN 773; /note="L->W: Decreased activation by positive allosteric modulators; when associated with W-833."; /evidence="ECO:0000269|PubMed:34194040"; MUTAGEN 781; /note="C->W: Increased activation by positive allosteric modulators; when associated with W-822."; /evidence="ECO:0000269|PubMed:34194040"; MUTAGEN 801; /note="F->A: Abolished G(s)-, G(q)- and G(i)-mediated G-protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38632411"; MUTAGEN 805; /note="K->A: Strongly decreased G(q)- and G(i)-mediated G-protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 809; /note="F->A: Strongly decreased G(q)- and G(i)-mediated G-protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 812; /note="L->A: Abolished calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38632411"; MUTAGEN 813; /note="I->A: Abolished calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38632411"; MUTAGEN 816; /note="I->A: Abolished calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38632411"; MUTAGEN 822; /note="I->W: Increased activation by positive allosteric modulators; when associated with W-781."; /evidence="ECO:0000269|PubMed:34194040"; MUTAGEN 825; /note="Y->A: Does not affect G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 828; /note="T->N: Increased G protein-coupled receptor signaling."; /evidence="ECO:0000269|PubMed:39658204"; MUTAGEN 829; /note="Y->A: Does not affect G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 833; /note="V->A: Does not affect G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 833; /note="V->W: Decreased activation by positive allosteric modulators; when associated with W-833."; /evidence="ECO:0000269|PubMed:34194040"; MUTAGEN 873..876; /note="RCST->ACSA: Abolished G(s)-, G(q)- and G(i)-mediated G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38632411"; MUTAGEN 881..888; /note="FKVAARAT->AKVAARAD: Decreased G(q)-mediated G protein-coupled receptor activity without affecting G(i)-mediated G protein-coupled signaling."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 884; /note="A->W: Decreased G(q)-mediated G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 887; /note="Missing: Decreased G(q)-mediated G protein-coupled receptor activity without affecting G(i)-mediated G protein-coupled signaling."; /evidence="ECO:0000269|PubMed:38326620"; MUTAGEN 888; /note="T->D: Mimics phosphorylation; strongly decreased calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:17376781"; MUTAGEN 888; /note="T->N,Q,K: Does not affect calcium-induced G protein-coupled receptor activity."; /evidence="ECO:0000269|PubMed:17376781"; MUTAGEN 888; /note="T->V: Decreased calcium-induced G protein-coupled receptor activity. Strongly decreased calcium-induced G protein-coupled receptor activity; when associated with A-895 and A-915."; /evidence="ECO:0000269|PubMed:9694886"; MUTAGEN 890..898; /note="RRSNVSRKR->AASNVSAAA: Increased localization to the plasma membrane."; /evidence="ECO:0000269|PubMed:20798521"; MUTAGEN 895; /note="S->A: Slightly decreased calcium-induced G protein-coupled receptor activity. Strongly decreased calcium-induced G protein-coupled receptor activity; when associated with A-888 and A-915."; /evidence="ECO:0000269|PubMed:9694886"; MUTAGEN 915; /note="S->A: Slightly decreased calcium-induced G protein-coupled receptor activity. Strongly decreased calcium-induced G protein-coupled receptor activity; when associated with A-888 and A-895."; /evidence="ECO:0000269|PubMed:9694886
uniprot
proteins
post_translational_modification
PTM: Phosphorylation at Thr-888 by PKC impairs coupling with G(q)/G(11) G proteins, while it does not affect G(i)/G(o)-coupling (PubMed:17376781, PubMed:38326620, PubMed:9694886). Phosphorylation at Ser-892 by PKC and Ser-899 by PKA promote plasma membrane localization (PubMed:20798521). {ECO:0000269|PubMed:17376781, ECO:0000269|PubMed:20798521, ECO:0000269|PubMed:38326620, ECO:0000269|PubMed:9694886}.; PTM: Ubiquitinated by RNF19A; which induces proteasomal degradation. {ECO:0000269|PubMed:16513638}.; PTM: N-glycosylated. {ECO:0000269|PubMed:16513638, ECO:0000269|PubMed:16740594, ECO:0000269|PubMed:20861236, ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:8702647}.
uniprot
proteins
protein_family
G protein-coupled receptor 3 family
uniprot
proteins
pubmed
10023897
uniprot
proteins
pubmed
10077597
uniprot
proteins
pubmed
10468915
uniprot
proteins
pubmed
10487661
uniprot
proteins
pubmed
10843194
uniprot
proteins
pubmed
11161843
uniprot
proteins
pubmed
11762699
uniprot
proteins
pubmed
11807402
uniprot
proteins
pubmed
12050233
uniprot
proteins
pubmed
12107202
uniprot
proteins
pubmed
12241879
uniprot
proteins
pubmed
12574188
uniprot
proteins
pubmed
12915654
uniprot
proteins
pubmed
14985373
uniprot
proteins
pubmed
15005845
uniprot
proteins
pubmed
15489334
uniprot
proteins
pubmed
15531522
uniprot
proteins
pubmed
15551332
uniprot
proteins
pubmed
15572418
uniprot
proteins
pubmed
15579740
uniprot
proteins
pubmed
15879434
uniprot
proteins
pubmed
16497624
uniprot
proteins
pubmed
16513638
uniprot
proteins
pubmed
16598859
uniprot
proteins
pubmed
16608894
uniprot
proteins
pubmed
16740594
uniprot
proteins
pubmed
17048213
uniprot
proteins
pubmed
17360426
uniprot
proteins
pubmed
17376781
uniprot
proteins
pubmed
17473068
uniprot
proteins
pubmed
17555508
uniprot
proteins
pubmed
17698911
uniprot
proteins
pubmed
18756473
uniprot
proteins
pubmed
19179454
uniprot
proteins
pubmed
19789209
uniprot
proteins
pubmed
20798521
uniprot
proteins
pubmed
20846291
uniprot
proteins
pubmed
20861236
uniprot
proteins
pubmed
21566075
uniprot
proteins
pubmed
21643651
uniprot
proteins
pubmed
22114145
uniprot
proteins
pubmed
22789683
uniprot
proteins
pubmed
23169696
uniprot
proteins
pubmed
23966241
uniprot
proteins
pubmed
25104082
uniprot
proteins
pubmed
25292184
uniprot
proteins
pubmed
25766501
uniprot
proteins
pubmed
26290606
uniprot
proteins
pubmed
26386835
uniprot
proteins
pubmed
27386547
uniprot
proteins
pubmed
27434672
uniprot
proteins
pubmed
27613866
uniprot
proteins
pubmed
32817431
uniprot
proteins
pubmed
32843625
uniprot
proteins
pubmed
33603117
uniprot
proteins
pubmed
34194040
uniprot
proteins
pubmed
34467854
uniprot
proteins
pubmed
34916296
uniprot
proteins
pubmed
37919470
uniprot
proteins
pubmed
38326620
uniprot
proteins
pubmed
38632411
uniprot
proteins
pubmed
39658204
uniprot
proteins
pubmed
7673400
uniprot
proteins
pubmed
7677761
uniprot
proteins
pubmed
7726161
uniprot
proteins
pubmed
7759551
uniprot
proteins
pubmed
7874174
uniprot
proteins
pubmed
7916660
uniprot
proteins
pubmed
8613532
uniprot
proteins
pubmed
8636323
uniprot
proteins
pubmed
8675635
uniprot
proteins
pubmed
8698326
uniprot
proteins
pubmed
8702647
uniprot
proteins
pubmed
8733126
uniprot
proteins
pubmed
8756555
uniprot
proteins
pubmed
8813042
uniprot
proteins
pubmed
8878438
uniprot
proteins
pubmed
9253358
uniprot
proteins
pubmed
9253359
uniprot
proteins
pubmed
9298824
uniprot
proteins
pubmed
9661634
uniprot
proteins
pubmed
9694886
uniprot
proteins
pubmed
9920108
uniprot
proteins
sequence_length
1078
uniprot
proteins
subcellular_location
SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15572418, ECO:0000269|PubMed:16740594, ECO:0000269|PubMed:17555508, ECO:0000269|PubMed:19789209, ECO:0000269|PubMed:20798521, ECO:0000269|PubMed:20861236, ECO:0000269|PubMed:22114145, ECO:0000269|PubMed:22789683, ECO:0000269|PubMed:25104082, ECO:0000269|PubMed:25766501, ECO:0000269|PubMed:26386835, ECO:0000269|PubMed:8702647}; Multi-pass membrane protein {ECO:0000269|PubMed:20861236}.
uniprot
proteins
transmembrane_region
TRANSMEM 611..636; /note="Helical; Name=1"; /evidence="ECO:0000269|PubMed:34194040, ECO:0007744|PDB:7M3E, ECO:0007744|PDB:7M3F, ECO:0007744|PDB:7M3G, ECO:0007744|PDB:7M3J"; TRANSMEM 649..668; /note="Helical; Name=2"; /evidence="ECO:0000269|PubMed:34194040, ECO:0007744|PDB:7M3E, ECO:0007744|PDB:7M3F, ECO:0007744|PDB:7M3G, ECO:0007744|PDB:7M3J"; TRANSMEM 675..698; /note="Helical; Name=3"; /evidence="ECO:0000269|PubMed:34194040, ECO:0007744|PDB:7M3E, ECO:0007744|PDB:7M3F, ECO:0007744|PDB:7M3G, ECO:0007744|PDB:7M3J"; TRANSMEM 723..745; /note="Helical; Name=4"; /evidence="ECO:0000269|PubMed:34194040, ECO:0007744|PDB:7M3E, ECO:0007744|PDB:7M3F, ECO:0007744|PDB:7M3G, ECO:0007744|PDB:7M3J"; TRANSMEM 770..789; /note="Helical; Name=5"; /evidence="ECO:0000269|PubMed:34194040, ECO:0007744|PDB:7M3E, ECO:0007744|PDB:7M3F, ECO:0007744|PDB:7M3G, ECO:0007744|PDB:7M3J"; TRANSMEM 806..828; /note="Helical; Name=6"; /evidence="ECO:0000269|PubMed:34194040, ECO:0007744|PDB:7M3E, ECO:0007744|PDB:7M3F, ECO:0007744|PDB:7M3G, ECO:0007744|PDB:7M3J"; TRANSMEM 833..854; /note="Helical; Name=7"; /evidence="ECO:0000269|PubMed:34194040, ECO:0007744|PDB:7M3E, ECO:0007744|PDB:7M3F, ECO:0007744|PDB:7M3G, ECO:0007744|PDB:7M3J
uniprot
proteins